Dr Alys Havard and Dr Danielle Tran present 'A multi-national study of the use, safety and effectiveness of smoking cessation pharmacotherapies during pregnancy'

Please click the link below to join the webinar:

https://uqz.zoom.us/j/84200625237?pwd=SkhtRkZMUkpkaExBTUlLbFhVV3N3Zz09
Passcode: 276315

In this webinar, the presenters will describe their current program of research examining the use, safety and effectiveness of prescription varenicline, nicotine replacement therapy and bupropion during pregnancy. These research questions will be addressed with population-based cohort studies using linked data from Australia, New Zealand, Norway and Sweden. Findings regarding the risk of congenital malformations in babies exposed to these pharmacotherapies during gestation will be presented.

Dr Alys Havard is a Senior Research Fellow based at both the National Drug and Alcohol Research Centre (NDARC) and the School of Population Health, UNSW Sydney. She is also a Deputy Director at NDARC. Dr Havard’s research uses large-scale linked data to study the use and effects of prescribed medicines in priority populations such as pregnant women and people with cardiovascular disease.

Dr Danielle Tran is a Research Fellow at the National Drug and Alcohol Research Centre, UNSW Sydney. Her research areas include the utilisation of medicines, health services and health outcomes, leveraging ‘big data’ in real-world settings. She currently leads analyses to examine the safety of smoking cessation pharmacotherapy in pregnancy.